In the present study, we have prospectively assessed the effect of NT-proBNP on the association of moderately reduced eGFR levels with 6-years CV mortality, independently of classical and new cardiovascular risk factors, including albuminuria and plasma C-reactive protein (CRP), in a population-based cohort of people with type 2 diabetes and eGFR >45 ml/min/1.73 m2.[11]–[12]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.